"It's More A Gut Feeling Rather Than Based On Really Truly Serious Data": FDA Panelist On Approving Moderna Boosters

Vaccine experts advising the Food and Drug Administration voted 19 to 0 Thursday to recommend authorization of an extra dose of Moderna Inc.'s MRNA Covid-19 shot, a key step in making booster doses available to millions more people.

A vaccine-advisory panel voted in favor of giving a Moderna booster shot at least six months after the second dose, to adults 65 years and older, as well as adults under 65 who are at high risk of severe Covid-19 or serious complications because of their jobs, living conditions or underlying medical conditions.

[...] Members of the FDA’s vaccine-advisory panel supported Moderna's booster dose even though the evidence for it was from a small study and had mixed results.

"It's more a gut feeling rather than based on really truly serious data," said Patrick Moore, a member of the committee and a professor of molecular genetics and biochemistry at the University of Pittsburgh School of Medicine. "The data itself is not strong, but it is certainly going in the direction that is supportive of this vote."

Moderna founders debut on Forbes' list of 400 richest Americans https://t.co/tMhFIm8uvZ pic.twitter.com/v9PFyZP4rt

— New York Post (@nypost) October 8, 2021